Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout
Side effects have led Vertex Pharmaceuticals to stop work on another Phase II drug candidate to treat a rare genetic disease called alpha-1 antitrypsin defiency, or AATD, the biotech disclosed Monday in its third-quarter earnings report.
Vertex is discontinuing research on the small molecule called VX-864 because of “non-serious rash events in some patients,” according to a press release. About three years ago, Vertex abandoned another AATD program, called VX-814, that made it to Phase II after seeing signs of liver damage. Vertex’s stock price moved down about 2% to $379 after markets closed Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
